Patients with blood tumors will receive international consultations.

The "China Anti-Cancer Association Blood Tumor Summit Forum and the First Tianjin International Blood Tumor Summit Forum" co-sponsored by china Cancer Association and Tianjin Cancer Hospital was held in Tianjin.
through this forum, Tianjin Cancer Hospital Hematology Oncology Department will join forces with the U.S. Moffitt Cancer Center hematology oncology department to conclude a sister department. In the future, patients who come to the haematology department of Tianjin Cancer Hospital will hopefully receive international consultation at the International Authoritative Oncology Center. "Every consultation, patients get a consultation plan from an international team of super specialists, " said Zhang Yixuan, director of the department of haematology at Tianjin Cancer Hospital. "Patients with malignant blood tumors have access to cutting-edge treatment concepts, the most accurate treatment options, state-of-the-art treatment technologies and medications that greatly improve cancer treatment and avoid misdiagnosis and mistreatment." At the same time, the latest and fastest clinical research will benefit patients.
Professor Zhang Yiyi introduced that common blood tumors mainly include leukemia, multiple myeloma and malignant lymphoma. Among them, the incidence of lymphoma increased year by year, acute leukemia is most well known, and multiple myeloma cognition is the lowest, misdiagnosis rate is the highest, and diagnosis is complex, the first diagnosis rate is less than 30%. At present, blood tumors in the treatment of generally to combine chemotherapy, hematopoietic stem cell transplantation and targeted treatment-based comprehensive treatment, the effect of early treatment is much better than the late stage. However, due to the complexity of the blood tumor itself, and many patients are already in the middle and late stage, how to achieve the precision of blood tumor, standardized diagnosis and treatment, improve the first diagnosis rate and survival of blood tumor patients, has become the topic of greatconcern.
Professor Zhang Yixuan said that through the use of the U.S. Moffitt Cancer Center's cutting-edge experimental platform, further in-depth clinical research and clinical trials of hematologic malignancies;
for patients, especially malignant blood tumors with complexity, can obtain the world's leading cancer center experts through international consultation between China and the United States, through the multidisciplinary cooperation between China and the United States to complete the development of patient diagnosis and treatment programs, to ensure that patients can get the most accurate, most suitable for their own personalized treatment programs, thereby greatly improving the quality of life and survival of blood tumor patients. (Zhou Wei)
.